Overview

A Study to Evaluate the Efficacy, Safety and Tolerability of TMC435 in Combination With PegIFN Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve or Treatment-Experienced, Chronic Hepatitis C Virus Genotype-4 Infected Patients

Status:
Completed

Trial end date:
2014-03-20

Target enrollment:

Participant gender:

Summary

The purpose of this study to evaluate the efficacy, safety and tolerability of TMC435 in combination with Peginterferon alfa-2a (PegINF alfa-2a) and ribavirin (RBV) in both treatment-naïve and treatment experienced, chronic hepatitis C (HCV) virus, genotype-4 infected patients.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen R&D Ireland

Treatments:

Peginterferon alfa-2a
Ribavirin
Simeprevir